Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Karyopharm Therapeutics stock

Learn how to easily invest in Karyopharm Therapeutics stock.

Karyopharm Therapeutics Inc is a biotechnology business based in the US. Karyopharm Therapeutics shares (KPTI) are listed on the NASDAQ and all prices are listed in US Dollars. Karyopharm Therapeutics employs 442 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Karyopharm Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KPTI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Karyopharm Therapeutics stock price (NASDAQ: KPTI)

Use our graph to track the performance of KPTI stocks over time.

Karyopharm Therapeutics shares at a glance

Information last updated 2022-06-24.
Latest market close$5.17
52-week range$4.02 - $14.73
50-day moving average $5.92
200-day moving average $6.98
Wall St. target price$12.38
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.42

Buy Karyopharm Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Karyopharm Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Karyopharm Therapeutics price performance over time

Historical closes compared with the close of $5.17 from 2022-06-24

1 week (2022-06-17) 16.44%
1 month (2022-05-22) N/A
3 months (2022-03-25) -29.27%
6 months (2021-12-22) N/A
1 year (2021-06-25) -52.96%
2 years (2020-06-26) -71.93%
3 years (2019-06-26) 6.06
5 years (2017-06-26) 9.52

Karyopharm Therapeutics financials

Revenue TTM $234.2 million
Gross profit TTM $57.4 million
Return on assets TTM -17.33%
Return on equity TTM -891.05%
Profit margin -46.14%
Book value $0.68
Market capitalisation $410.6 million

TTM: trailing 12 months

Karyopharm Therapeutics share dividends

We're not expecting Karyopharm Therapeutics to pay a dividend over the next 12 months.

Karyopharm Therapeutics share price volatility

Over the last 12 months, Karyopharm Therapeutics's shares have ranged in value from as little as $4.02 up to $14.73. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karyopharm Therapeutics's is -0.1665. This would suggest that Karyopharm Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Karyopharm Therapeutics has bucked the trend.

Karyopharm Therapeutics overview

Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Frequently asked questions

What percentage of Karyopharm Therapeutics is owned by insiders or institutions?
Currently 8.855% of Karyopharm Therapeutics shares are held by insiders and 90.972% by institutions.
How many people work for Karyopharm Therapeutics?
Latest data suggests 442 work at Karyopharm Therapeutics.
When does the fiscal year end for Karyopharm Therapeutics?
Karyopharm Therapeutics's fiscal year ends in December.
Where is Karyopharm Therapeutics based?
Karyopharm Therapeutics's address is: 85 Wells Avenue, Newton, MA, United States, 02459
What is Karyopharm Therapeutics's ISIN number?
Karyopharm Therapeutics's international securities identification number is: US48576U1060
What is Karyopharm Therapeutics's CUSIP number?
Karyopharm Therapeutics's Committee on Uniform Securities Identification Procedures number is: 48576U106

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site